Literature DB >> 18443116

Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Pauliina Kärpänoja1, Solja T Nyberg, Miika Bergman, Tinna Voipio, Pirkko Paakkari, Pentti Huovinen, Hannu Sarkkinen.   

Abstract

The association between trimethoprim-sulfamethoxazole use and resistance among the major respiratory tract pathogens was investigated by comparing regional consumption of the drug to regional resistance in the following year in 21 central hospital districts in Finland. A total of 23,530 Streptococcus pneumoniae isolates, 28,320 Haemophilus influenzae isolates, and 14,138 Moraxella catarrhalis isolates were tested for trimethoprim-sulfamethoxazole susceptibility during the study period (1998-2004). Among the S. pneumoniae isolates, a statistically significant connection was found between regional consumption and resistance. No statistically significant connection was found between regional trimethoprim-sulfamethoxazole use and resistance among H. influenzae and M. catarrhalis isolates. According to our results, it seems that only in pneumococci can the development of trimethoprim-sulfamethoxazole resistance be influenced by restricting its use. However, trimethoprim-sulfamethoxazole remains an important antimicrobial agent because of its reasonable price. Hence, resistance to trimethoprim-sulfamethoxazole among these pathogens needs continuous monitoring.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443116      PMCID: PMC2443875          DOI: 10.1128/AAC.01118-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Hoban; G V Doern; A C Fluit; M Roussel-Delvallez; R N Jones
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

2.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998.

Authors:  D F Sahm; M E Jones; M L Hickey; D R Diakun; S V Mani; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

3.  Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents.

Authors:  M Pihlajamäki; P Kotilainen; T Kaurila; T Klaukka; E Palva; P Huovinen
Journal:  Clin Infect Dis       Date:  2001-07-20       Impact factor: 9.079

4.  The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens.

Authors:  M Cizman; M Pokorn; K Seme; A Orazem; M Paragi
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

5.  Antibiotic use by indication: a basis for active antibiotic policy in the community.

Authors:  U M Rautakorpi; T Klaukka; P Honkanen; M Mäkelä; T Nikkarinen; E Palva; R Roine; H Sarkkinen; P Huovinen
Journal:  Scand J Infect Dis       Date:  2001

Review 6.  Resistance to trimethoprim-sulfamethoxazole.

Authors:  P Huovinen
Journal:  Clin Infect Dis       Date:  2001-05-04       Impact factor: 9.079

7.  Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.

Authors:  C García-Rey; L Aguilar; F Baquero; J Casal; J E Martín
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

8.  Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001.

Authors:  Miika Bergman; Solja Huikko; Marja Pihlajamäki; Pekka Laippala; Erkki Palva; Pentti Huovinen; Helena Seppälä
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

9.  Clonal spread of resistant pneumococci despite diminished antimicrobial use.

Authors:  Vilhjalmur A Arason; Adalsteinn Gunnlaugsson; Johann A Sigurdsson; Helga Erlendsdottir; Sigurdur Gudmundsson; Karl G Kristinsson
Journal:  Microb Drug Resist       Date:  2002       Impact factor: 3.431

10.  Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection.

Authors:  G Kahlmeter; P Menday; O Cars
Journal:  J Antimicrob Chemother       Date:  2003-11-12       Impact factor: 5.790

View more
  12 in total

1.  Trimethoprim-sulfamethoxazole prophylaxis and antibiotic nonsusceptibility in invasive pneumococcal disease.

Authors:  Heidi M Soeters; Anne von Gottberg; Cheryl Cohen; Vanessa Quan; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

2.  Comparison of Mycobacterium tuberculosis complex Yield and Contamination Rates using Lowenstein-Jensen with and without Antibiotics in Western Kenya.

Authors:  A Okumu; K McCarthy; J Orwa; J Williamson; S Musau; H Alexander; S Cavanaugh; S Modi; K Cain
Journal:  J Med Sci Clin Res       Date:  2017

3.  Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007.

Authors:  L Blaettler; D Mertz; R Frei; L Elzi; A F Widmer; M Battegay; U Flückiger
Journal:  Infection       Date:  2009-12       Impact factor: 3.553

4.  Association between antimicrobial consumption and resistance in Escherichia coli.

Authors:  Miika Bergman; Solja T Nyberg; Pentti Huovinen; Pirkko Paakkari; Antti J Hakanen
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

5.  Genomic identification of a novel co-trimoxazole resistance genotype and its prevalence amongst Streptococcus pneumoniae in Malawi.

Authors:  Jennifer E Cornick; Simon R Harris; Christopher M Parry; Michael J Moore; Chikondi Jassi; Arox Kamng'ona; Benard Kulohoma; Robert S Heyderman; Stephen D Bentley; Dean B Everett
Journal:  J Antimicrob Chemother       Date:  2013-09-29       Impact factor: 5.790

6.  Antimicrobial resistance trends among community-acquired respiratory tract pathogens in Greece, 2009-2012.

Authors:  Sofia Maraki; Ioannis S Papadakis
Journal:  ScientificWorldJournal       Date:  2014-01-27

7.  Inactivation of the Thymidylate Synthase thyA in Non-typeable Haemophilus influenzae Modulates Antibiotic Resistance and Has a Strong Impact on Its Interplay with the Host Airways.

Authors:  Irene Rodríguez-Arce; Sara Martí; Begoña Euba; Ariadna Fernández-Calvet; Javier Moleres; Nahikari López-López; Montserrat Barberán; José Ramos-Vivas; Fe Tubau; Carmen Losa; Carmen Ardanuy; José Leiva; José E Yuste; Junkal Garmendia
Journal:  Front Cell Infect Microbiol       Date:  2017-06-20       Impact factor: 5.293

8.  Evidence for Human Streptococcus pneumoniae in wild and captive chimpanzees: A potential threat to wild populations.

Authors:  Sophie Köndgen; Sebastien Calvignac-Spencer; Kim Grützmacher; Verena Keil; Kerstin Mätz-Rensing; Kathrin Nowak; Sonja Metzger; John Kiyang; Antina Lübke-Becker; Tobias Deschner; Roman M Wittig; Felix Lankester; Fabian H Leendertz
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

9.  Pediatric Bacterial Meningitis Surveillance in Niger: Increased Importance of Neisseria meningitidis Serogroup C, and a Decrease in Streptococcus pneumoniae Following 13-Valent Pneumococcal Conjugate Vaccine Introduction.

Authors:  Mamadou Kourna Hama; Dam Khan; Boubou Laouali; Catherine Okoi; Abdoulaye Yam; Moussa Haladou; Archibald Worwui; Peter Sylvanus Ndow; Ricardo Nse Obama; Jason M Mwenda; Joseph Biey; Bernard Ntsama; Brenda A Kwambana-Adams; Martin Antonio
Journal:  Clin Infect Dis       Date:  2019-09-05       Impact factor: 9.079

10.  A Solution to Antifolate Resistance in Group B Streptococcus: Untargeted Metabolomics Identifies Human Milk Oligosaccharide-Induced Perturbations That Result in Potentiation of Trimethoprim.

Authors:  Schuyler A Chambers; Rebecca E Moore; Kelly M Craft; Harrison C Thomas; Rishub Das; Shannon D Manning; Simona G Codreanu; Stacy D Sherrod; David M Aronoff; John A McLean; Jennifer A Gaddy; Steven D Townsend
Journal:  mBio       Date:  2020-03-17       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.